Major study aims to spare patients painful liver biopsies
NCT ID NCT06986447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 1,689 adults with fatty liver disease (MASLD) or MASLD with increased alcohol intake (MetALD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression. The goal is to reduce the need for liver biopsies in future research and clinical care. Participants will be monitored for serious liver and heart outcomes over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Liver Health
Chandler, Arizona, 85224, United States
-
Arizona Liver Health
Peoria, Arizona, 85381, United States
-
Arizona Liver Health
Tucson, Arizona, 85712, United States
-
CRIOH
Westlake, Ohio, 44145, United States
-
Houston Research Institute - Dairy Ashford
Houston, Texas, 77079, United States
-
Houston Research Institute - Medical Center
Houston, Texas, 77030, United States
-
Houston Research Institute - Pasadena
Pasadena, Texas, 77505, United States
-
Houston Research Institute - Sugar Land
Sugar Land, Texas, 77478, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Seaweed extract may tackle fatty liver Disease—A trial puts it to the test
- Can Weight-Loss surgery rewire the Liver's energy engine?
- Wheat sensitivity linked to fatty liver? a new study investigates
- Hidden liver risk in type 1 diabetes: a new study investigates
- Heart scans could flag Who's at risk after liver shunt